Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

New non‐canonical function of catalytically dead hexokinase 1 in ovarian cancer

View through CrossRef
Hexokinases (HKs) have been found amplified in primary cancer cells, with the amplification of HK1 reported commonly in ovarian cancer cells. The function of HKs extends beyond glucose phosphorylation, and HKs serve as regulatory proteins in tumorigenesis. We addressed the non‐canonical roles of HK1 in ovarian cancer cells by examining the effects of the deletions of HK1 and HK2 in TOV‐112D ovarian adenocarcinoma cells. We reverted these effects by re‐introducing wild‐type HK1 and HK2, and we compared the HK1 revertant with the knock‐in of catalytically‐dead HK1 p.D656A. We subjected these cells to a battery of metabolic and proliferation assays and targeted GCxGC‐MS metabolomics. When expressed in vitro , the p.D656A mutant did not manifest a measurable K M and exhibited V max lower by almost two orders of magnitude when compared to the wild‐type enzyme. Knock‐in of HK1 p.D656A into HK1 KO cells reverted the HK1 KO‐induced effects in a broad range of assays, including the alamarBlue cell viability assay under low glucose conditions, the NADPH/NADP and NAD/NADH ratios, and glutathione levels in metformin‐treated cells. In the presence of 0.4 mM glucose, the phenotype of HK1 p.D656A knock‐in cells resembled the phenotype of cells with deleted HK2 but not those with deleted HK1 with regards to the levels of TCA intermediates, aspartate and cysteine, and glutamate. Moreover, HK1 deletion increased the levels of branched amino acids, which was completely eliminated by the expression of catalytically‐dead HK1. The HK1 deletion (but not HK2 deletion) suppressed the growth of xenotransplanted ovarian cancer cells, and nearly abolished the tumor growth when the mice were fed the glucose‐free diet. In summary, we provided the evidence that HK1 is involved in the so far unknown glycolysis‐independent moonlighting function and influences metabolism even in the glucose‐free conditions.
Title: New non‐canonical function of catalytically dead hexokinase 1 in ovarian cancer
Description:
Hexokinases (HKs) have been found amplified in primary cancer cells, with the amplification of HK1 reported commonly in ovarian cancer cells.
The function of HKs extends beyond glucose phosphorylation, and HKs serve as regulatory proteins in tumorigenesis.
We addressed the non‐canonical roles of HK1 in ovarian cancer cells by examining the effects of the deletions of HK1 and HK2 in TOV‐112D ovarian adenocarcinoma cells.
We reverted these effects by re‐introducing wild‐type HK1 and HK2, and we compared the HK1 revertant with the knock‐in of catalytically‐dead HK1 p.
D656A.
We subjected these cells to a battery of metabolic and proliferation assays and targeted GCxGC‐MS metabolomics.
When expressed in vitro , the p.
D656A mutant did not manifest a measurable K M and exhibited V max lower by almost two orders of magnitude when compared to the wild‐type enzyme.
Knock‐in of HK1 p.
D656A into HK1 KO cells reverted the HK1 KO‐induced effects in a broad range of assays, including the alamarBlue cell viability assay under low glucose conditions, the NADPH/NADP and NAD/NADH ratios, and glutathione levels in metformin‐treated cells.
In the presence of 0.
4 mM glucose, the phenotype of HK1 p.
D656A knock‐in cells resembled the phenotype of cells with deleted HK2 but not those with deleted HK1 with regards to the levels of TCA intermediates, aspartate and cysteine, and glutamate.
Moreover, HK1 deletion increased the levels of branched amino acids, which was completely eliminated by the expression of catalytically‐dead HK1.
The HK1 deletion (but not HK2 deletion) suppressed the growth of xenotransplanted ovarian cancer cells, and nearly abolished the tumor growth when the mice were fed the glucose‐free diet.
In summary, we provided the evidence that HK1 is involved in the so far unknown glycolysis‐independent moonlighting function and influences metabolism even in the glucose‐free conditions.

Related Results

Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract Aim: Epithelial ovarian cancer is one of the most lethal female cancers. It is a heterogeneous group of neoplasms and the different histologic subtypes are ...
Abstract 2208: Clinicopathological and genetic study of ovarian cancer in Algerian women: First report
Abstract 2208: Clinicopathological and genetic study of ovarian cancer in Algerian women: First report
Abstract Background: Ovarian cancer represents the fourth most common cause of mortality among Algerian women. Of all gynecological malignancies, ovarian cancer caus...
Abstract 4998: Lipolysis-stimulated lipoprotein receptor (LSR) can be a novel therapeutic target of ovarian cancer
Abstract 4998: Lipolysis-stimulated lipoprotein receptor (LSR) can be a novel therapeutic target of ovarian cancer
Abstract Objective:Ovarian cancer is the most lethal gynecological malignancy. Five-year survival of advanced ovarian cancer patients remains less than 50% and the m...
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract Introduction: There are many factors that affect breast and ovarian cancer incidence. Genetics, obesity, parity, age at menarche, age at first pregnancy, an...

Back to Top